Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
The British Library has selected Clarivate (NYSE:CLVT) to provide its library services and discovery platforms, implementing Alma, Primo VE, and Rapido solutions. This decision builds upon a 20-year partnership and aims to create a more cohesive, streamlined, and secure experience.
The British Library, one of the world's largest libraries with a collection of 170 million items, will become the 43rd National and State library globally to adopt Alma. The implementation will unify platform operations, improve user experience, and enhance future services. The Rapido system will be used to streamline interlibrary loan processes, supporting resource sharing within the academic and research community.
Clarivate Plc (NYSE: CLVT) has announced it will release its fourth quarter and full year 2024 financial results before market opening on Wednesday, February 19, 2025. The company will make the press release and earnings supplement with financial information available on their investor website. Following the release, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.
BioWorld, published by Clarivate (NYSE:CLVT), has released its comprehensive 2024 Year in Review series analyzing key developments in biopharma, medtech, and scientific innovation. The report highlights significant therapeutic breakthroughs in psychiatry, oncology, women's health, and infectious diseases.
Key findings include the industry's resilience despite challenges, with biopharma financing and deal values rebounding amid over 18,000 job losses. Notable developments include GLP-1 receptor agonists' expansion into new therapeutic areas, significant progress in AI-driven medtech in APAC, and breakthrough cancer research data from trials like Checkmate-067 and Keynote-006.
The report also covers important regulatory changes, including the end of the Chevron doctrine affecting agency authority, and Medicare coverage challenges for emerging technologies. European biotech funding showed improvement in 2024, particularly in antibody-drug conjugates (ADCs) and CNS treatments.
Clarivate (NYSE:CLVT) has launched DRG Fusion, a new analytics platform designed to support commercial analytics in life sciences. The platform integrates real-world data from medical and pharmacy claims to help biopharma and medtech organizations optimize their commercial strategies.
The platform features modular data analytics products with configurable dashboards supporting patient journey analysis, commercial targeting, market access optimization, and patient segmentation. Fusion streamlines data management by providing ready-made visuals and tables to accelerate commercial decisions.
The company plans to introduce AI-driven and self-service features to Fusion in 2025, demonstrating its commitment to delivering user-centric solutions for healthcare challenges.
Clarivate (NYSE:CLVT) has released its twelfth annual Drugs to Watch™ report, identifying 11 potential blockbuster therapies expected to achieve significant market success or transform treatment paradigms by 2030. The report highlights innovations in obesity, oncology, and gene therapy, powered by Clarivate's Cortellis intelligence suite.
Key featured drugs include AWIQLI® (first weekly insulin), CagriSema (obesity treatment), COBENFY™ (schizophrenia therapy), and EBGLYSS™ (atopic dermatitis treatment). The report also analyzes the chronic disease market in Mainland China and explores industry trends including AI integration, radiopharmaceutical theranostics, and the growing importance of real-world data in healthcare decisions.
The analysis demonstrates Clarivate's strong track record, with 12 out of 13 molecules identified in last year's report already approved and launched.
Clarivate (NYSE:CLVT) has announced a new $500 million share repurchase program for its outstanding ordinary shares, effective from January 1, 2025, through December 31, 2026. This program replaces the current one ending December 31, 2024, under which the company repurchased $300 million of shares, including $200 million in Q3-Q4 2024.
Additionally, Clarivate has prepaid $75 million of term-loan debt in Q4, bringing total 2024 prepayments to $133 million. The new buyback program, part of the company's Value Creation Plan, allows for open-market purchases through various methods, including Rule 10b5-1 trading plans, subject to market conditions and regulatory requirements.
Clarivate (NYSE: CLVT) has launched AI Search in Derwent™, an AI-powered patent search solution. The tool integrates AI with the Derwent World Patents Index (DWPI)™ to enhance innovation decision-making by delivering faster and more relevant patent search results. The AI Search leverages a language transformer model to understand context and retrieve pertinent results from over 160 million patent records. This solution aids patent researchers, attorneys, and IP professionals in conducting accurate first-pass patentability searches and validating results to ensure no relevant records are missed. DWPI, covering more than 120 million patents and over 62 million invention families, underpins the AI Search with manually written abstracts summarizing each invention's novelty and advantage. Gordon Samson, President of Intellectual Property at Clarivate, highlighted that this technology reduces the number of patents professionals need to review, thus speeding up and improving decision-making.
Clarivate and the Chinese Academy of Sciences have released their 11th annual Research Fronts 2024 report, identifying 125 dynamic research specialties in sciences and social sciences. The report highlights 110 'hot' and 15 'emerging' research fronts, including studies on monoclonal antibodies for early Alzheimer's treatment and Generative AI in education.
The analysis, based on Clarivate's Essential Science Indicators database, tracks patterns of co-citation among scientific papers. The accompanying comparative analysis shows the United States leading research activities across 11 areas, followed by Mainland China, with the UK, Germany, and France completing the top five countries.
Clarivate Plc (NYSE: CLVT) announced that Daikin Industries has selected IPfolio™ to optimize its intellectual property assets management. The leading air conditioner manufacturer will use this cloud-based solution to enhance operational efficiency, manage increasing IP filing volumes, and eliminate manual processes. IPfolio will be implemented across Daikin's global offices to facilitate collaboration through connected services and integrations. The solution's configurability will help Daikin meet its unique IP asset management needs while enabling more confident strategic decision-making and sustainable growth.
BioWorld, published by Clarivate (NYSE:CLVT), has launched 'Healing the Health Divide,' a seven-part series examining disparities in women's health research and funding. The series reveals that only 15% of venture capital funding in 2023 went to women's health-focused biopharma companies, while just 8% of funded companies included women's health assets. Key findings show that women's health deals since 2019 represent only 18.5% of all analyzed deals from 473 companies.
The series explores gender bias in research, untapped market potential, and efforts to improve diagnosis and treatment of conditions like endometriosis and cardiovascular disease, which disproportionately affect women.